Publications by authors named "Steven Whitebread"

Claim this Profile
T
The activities of drug inactive ingredients on biological targets.
Joshua Pottel, Duncan Armstrong, Ling Zou, Alexander Fekete, Xi-Ping Huang, Steven Whitebread

Science· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
Folkert Reck, Alun Bermingham, Johanne Blais, Vladimir Capka, Taryn Cariaga, Steven Whitebread

Bioorg Med Chem Lett· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reverse translation of adverse event reports paves the way for de-risking preclinical off-targets.
Mateusz Maciejewski, Eugen Lounkine, Steven Whitebread, Pierre Farmer, William DuMouchel

Elife· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Implications of Dynamic Occupancy, Binding Kinetics, and Channel Gating Kinetics for hERG Blocker Safety Assessment and Mitigation.
Robert A Pearlstein, K Andrew MacCannell, Gül Erdemli, Sarita Yeola, Gabriel Helmlinger, Steven Whitebread

Curr Top Med Chem· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Secondary pharmacology: screening and interpretation of off-target activities - focus on translation.
Steven Whitebread, Berengere Dumotier, Duncan Armstrong, Alexander Fekete, Shanni Chen

Drug Discov Today· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A screening pattern recognition method finds new and divergent targets for drugs and natural products.
Anne Mai Wassermann, Eugen Lounkine, Laszlo Urban, Steven Whitebread, Shanni Chen

ACS Chem Biol· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Matched molecular pair analysis: significance and the impact of experimental uncertainty.
Christian Kramer, Julian E Fuchs, Steven Whitebread, Peter Gedeck, Klaus R Liedl

J Med Chem· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reducing safety-related drug attrition: the use of in vitro pharmacological profiling.
Joanne Bowes, Andrew J Brown, Jacques Hamon, Wolfgang Jarolimek, Arun Sridhar, Steven Whitebread

Nat Rev Drug Discov· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Large-scale prediction and testing of drug activity on side-effect targets.
Eugen Lounkine, Michael J Keiser, Steven Whitebread, Dmitri Mikhailov, Jacques Hamon

Nature· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors.
Michael D Shultz, Xueying Cao, Christine H Chen, Young Shin Cho, Nicole R Davis, Steven Whitebread

J Med Chem· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro safety pharmacology profiling: what else beyond hERG?
Jacques Hamon, Steven Whitebread, Valerie Techer-Etienne, Helene Le Coq, Kamal Azzaoui

Future Med Chem· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mapping adverse drug reactions in chemical space.
Josef Scheiber, Jeremy L Jenkins, Sai Chetan K Sukuru, Andreas Bender, Dmitri Mikhailov, Steven Whitebread

J Med Chem· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gaining insight into off-target mediated effects of drug candidates with a comprehensive systems chemical biology analysis.
Josef Scheiber, Bin Chen, Mariusz Milik, Sai Chetan K Sukuru, Andreas Bender, Steven Whitebread

J Chem Inf Model· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2-Cycloalkyl phenoxyacetic acid CRTh2 receptor antagonists.
David A Sandham, Clive Aldcroft, Urs Baettig, Lucy Barker, David Beer, Steven Whitebread

Bioorg Med Chem Lett· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure.
Andreas Bender, Josef Scheiber, Meir Glick, John W Davies, Kamal Azzaoui, Steven Whitebread

ChemMedChem· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modeling promiscuity based on in vitro safety pharmacology profiling data.
Kamal Azzaoui, Jacques Hamon, Bernard Faller, Steven Whitebread, Edgar Jacoby

ChemMedChem· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ABP688, a novel selective and high affinity ligand for the labeling of mGlu5 receptors: identification, in vitro pharmacology, pharmacokinetic and biodistribution studies.
Samuel Hintermann, Ivo Vranesic, Hans Allgeier, Armin Brülisauer, Daniel Hoyer, Steven Whitebread

Bioorg Med Chem· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-throughput in vitro profiling assays: lessons learnt from experiences at Novartis.
Bernard Faller, Jianling Wang, Alfred Zimmerlin, Leslie Bell, Jacques Hamon, Steven Whitebread

Expert Opin Drug Metab Toxicol· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development.
Steven Whitebread, Jacques Hamon, Dejan Bojanic, Laszlo Urban

Drug Discov Today· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and SAR of potent, orally available and brain-penetrable 5,6-dihydro-4H-3-thia-1-aza-benzo[e]azulen- and 4,5-dihydro-6-oxa-3-thia-1-aza-benzo[e]azulen derivatives as neuropeptide Y Y5 receptor antagonists.
Heinrich Rueeger, Marc Gerspacher, Peter Buehlmayer, Pascal Rigollier, Yasuchika Yamaguchi, Steven Whitebread

Bioorg Med Chem Lett· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis